News and features

Epistem plc (LSE: EHP), the UK epithelial stem cell company, announced today that data on its cancer stem cell assays will be presented at the international meeting of the American Association for Cancer Research (AACR) at the San Diego Convention Centre, California, USA from 13^th to 16^th April 2008.

7/4/2008

Epistem (LSE:EHP) announced today that Exponential Biotherapies, Inc (EBI). of Virginia, USA, have contracted Epistem to provide their specialised preclinical efficacy testing services for agents likely to protect the gastrointestinal tract against radiation damage.  The first compound that Epistem will assess is EBI’s lead candidate drug, EA-230, which is a small peptide immunoregulator, which has shown the potential to treat (minimise) radiation insult and could therefore be administered following a terrorist nuclear attack to reduce the level of intestinal related radiation sickness.

3/4/2008

Epistem plc (LSE:EHP) announced today that it had successfully completed a preliminary study with AstraZeneca for the use of its proprietary, minimally invasive plucked human hair biomarker technology to help steer oncology drug development.

28/1/2008